Fintel reports that on December 10, 2024, JMP Securities initiated coverage of Solid Biosciences (NasdaqGS:SLDB) with a Market Outperform recommendation.
Analyst Price Forecast Suggests 252.02% Upside
As of December 3, 2024, the average one-year price target for Solid Biosciences is $17.78/share. The forecasts range from a low of $12.12 to a high of $29.40. The average price target represents an increase of 252.02% from its latest reported closing price of $5.05 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Solid Biosciences is 5MM, an increase of ∞%. The projected annual non-GAAP EPS is -2.23.
What is the Fund Sentiment?
There are 204 funds or institutions reporting positions in Solid Biosciences. This is an increase of 87 owner(s) or 74.36% in the last quarter. Average portfolio weight of all funds dedicated to SLDB is 0.06%, an increase of 36.87%. Total shares owned by institutions decreased in the last three months by 0.82% to 37,374K shares. 
The put/call ratio of SLDB is 0.10, indicating a bullish outlook.
What are Other Shareholders Doing?
Perceptive Advisors holds 6,907K shares representing 17.29% ownership of the company. No change in the last quarter.
Ra Capital Management holds 4,330K shares representing 10.84% ownership of the company. No change in the last quarter.
Bain Capital Life Sciences Investors holds 4,035K shares representing 10.10% ownership of the company. No change in the last quarter.
Vestal Point Capital holds 2,800K shares representing 7.01% ownership of the company. In its prior filing, the firm reported owning 2,665K shares , representing an increase of 4.82%. The firm increased its portfolio allocation in SLDB by 31.36% over the last quarter.
Siren, L.L.C. holds 2,749K shares representing 6.88% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
